Can anyone offer a plausible explanation as to why Acadia hasn't proceeded with the final stage trial in Fragile X when the trial results to date have been so positive?
Given that a successful trial and subsequent approval would generate considerable revenue to NEU, surely NEU has protected themselves against Acadia not proceeding in a timely manner?
I'm beyond confused - can someone help me?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$18.91 |
Change
0.310(1.67%) |
Mkt cap ! $2.390B | |||
| Open | High | Low | Value | Volume |
| $18.77 | $19.14 | $18.55 | $4.645M | 246.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 40 | $18.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.92 | 7 | 1 |
View Market Depth
| Last trade - 13.14pm 12/09/2025 (20 minute delay) ? |
| NEU (ASX) Chart |